The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Abstract
BACKGROUND: Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis. METHODS: We performed randomized, double-blind, placebo-controlled trials involving adults who had moderate-to-severe atopic dermatitis despite treatment with topical glucocorticoids and calcineurin inhibitors. Dupilumab was evaluated as monotherapy in two 4-week trials and in one 12-week trial and in combination with topical glucocorticoids in another 4-week study. End points included the Eczema Area and Severity Index (EASI) score, the investigator's global assessment score, pruritus, safety assessments, serum biomarker levels, and disease transcriptome. RESULTS: In the 4-week monotherapy studies, dupilumab resulted in rapid and dose-dependent improvements in clinical indexes, biomarker levels, and the transcriptome. The results of the 12-week study of dupilumab monotherapy reproduced and extended the 4-week findings: 85% of patients in the dupilumab group, as compared with 35% of those in the placebo group, had a 50% reduction in the EASI score (EASI-50, with higher scores in the EASI indicating greater severity of eczema) (P<0.001); 40% of patients in the dupilumab group, as compared with 7% in the placebo group, had a score of 0 to 1 (indicating clearing or near-clearing of skin lesions) on the investigator's global assessment (P<0.001); and pruritus scores decreased (indicating a reduction in itch) by 55.7% in the dupilumab group versus 15.1% in the placebo group (P<0.001). In the combination study, 100% of the patients in the dupilumab group, as compared with 50% of those who received topical glucocorticoids with placebo injection, met the criterion for EASI-50 (P=0.002), despite the fact that patients who received dupilumab plus glucocorticoids used less than half the amount of topical glucocorticoids used by those who received placebo plus the topical medication (P=0.16). Adverse events, such as skin infection, occurred more frequently with placebo; nasopharyngitis and headache were the most frequent adverse events with dupilumab. CONCLUSIONS: Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity. Side-effect profiles were not dose-limiting. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers, NCT01259323, NCT01385657, NCT01639040, and NCT01548404.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Kunz, B., Oranje, A. P., Labrèze, L., Stalder, J.-F., Ring, J., & Taïeb, A. (1997) · Dermatology · doi:10.1159/000245677 · Cited by 1,046
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citationGuidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citationPhan, N., Blome, C., Fritz, F., Gerss, J., Reich, A., Ebata, T., Augustin, M., Szepietowski, J., & Ständer, S. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1246 · Cited by 575
The 5-D itch scale: a new measure of pruritus
Elman, S., Hynan, L. S., Gabriel, V., & Mayo, M. J. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09586.x · Cited by 540
Suárez-Fariñas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., de Guzman Strong, C., Krueger, J. G., & Guttman-Yassky, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.046 · Cited by 483
Self-citationSchram, M. E., Spuls, P. I., Leeflang, M. M. G., Lindeboom, R., Bos, J. D., & Schmitt, J. (2012) · Allergy · doi:10.1111/j.1398-9995.2011.02719.x · Cited by 383
Guidelines for treatment of atopic eczema (atopic dermatitis) Part II
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04636.x · Cited by 360
Self-citationExtrinsic and intrinsic types of atopic dermatitis
Tokura, Y. (2010) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2010.02.008 · Cited by 349
Skin Barrier Disruption: A Requirement for Allergen Sensitization?
De Benedetto, A., Kubo, A., & Beck, L. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.435 · Cited by 317
Self-citationSchmid(‐Grendelmeier), P., Simon, D., Simon, H., Akdis, C. A., & Wüthrich, B. (2001) · Allergy · doi:10.1034/j.1398-9995.2001.00144.x · Cited by 279
Epidemiology of atopic dermatitis: a review
DaVeiga, S. P. (2012) · Allergy and Asthma Proceedings · doi:10.2500/aap.2012.33.3569 · Cited by 236
Keratin 16 regulates innate immunity in response to epidermal barrier breach
Lessard, J. C., Piña-Paz, S., Rotty, J. D., Hickerson, R. P., Kaspar, R. L., Balmain, A., & Coulombe, P. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309576110 · Cited by 204
Consensus guidelines in diagnosis and treatment of atopic dermatitis
Eichenfield, L. F. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00569.x · Cited by 87
bbe, J. L., Friedlander, S. F., Cribier, B. J., Morren, M., ez, A. G. A.-D., Gelmetti, C. M., Hofmann, H., Houwing, R. H., Kownacki, S., Langley, R. G. B., et al. (2006) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200607020-00005 · Cited by 64
Comparative Effectiveness of Topical Calcineurin Inhibitors in Adult Patients with Atopic Dermatitis
Tsibris, H. C., & Qureshi, A. A. (2012) · American Journal of Clinical Dermatology · doi:10.2165/11597780-000000000-00000 · Cited by 57
Schram, M. E., Spuls, P. I., Spuls, P.-H. I., et al. (2011) · Cited by 34
Cited by
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationWeidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationMacrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Metadata
- Authors
- Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., Ardeleanu, M., Weinstein, S. P., Pirozzi, G., Guttman-Yassky, E., Suárez-Fariñas, M., Hager, M. D., Stahl, N., Yancopoulos, G. D., & Radin, A. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-10
- Volume
- 371
- Issue
- 2
- Pages
- 130-139
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118630839
- Cited by
- 1,421
- References
- 19
- FWCI
- 121.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.